Adaptimmune Therapeutics Stock (NASDAQ: ADAP) stock price, news, charts, stock research, profile.
You can purchase shares of Adaptimmune Therapeutics (NASDAQ:ADAP) through any online brokerage.
Other companies in Adaptimmune Therapeutics’s space includes: Ultragenyx Pharmaceutical (NASDAQ:RARE), Avidity Biosciences (NASDAQ:RNA), BeiGene (NASDAQ:ONC), Sarepta Therapeutics (NASDAQ:SRPT) and Neurocrine Biosciences (NASDAQ:NBIX).
Adaptimmune Therapeutics has a consensus price target of $3.86.
The stock price for Adaptimmune Therapeutics (NASDAQ: ADAP) is $0.6822 last updated January 10, 2025 at 4:01 AM EST.
There are no upcoming dividends for Adaptimmune Therapeutics.
Adaptimmune Therapeutics’s Q4 earnings are confirmed for Wednesday, March 5, 2025.
There is no upcoming split for Adaptimmune Therapeutics.
Adaptimmune Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.